This report on the uses of nucleic acid amplification (NAA) tests for diagnosis of TB is based on contributions of an expert panel of consultants convened by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL).
This report presents results from an expert panel convened by CDC to examine the current status of rapid drug-resistance (DR) testing in the United States; to research published evidence and current guidelines; and to provide guidance and make recommendations to CDC for developing a system to provide access to rapid drug-susceptibility testing to all TB control programs in the United States. The panel recommended that CDC establish regional laboratories to provide molecular drug-resistance testing services to state and local TB programs.
This report provides World Health Organization (WHO) member states with guidance on preventing TB transmission in healthcare facilities, congregate settings, and households. It focuses on what to do and how to prioritize TB infection control at national levels and includes recommendations for national managerial activities. The report updates or presents new or increased emphasis on the particular administrative and environmental controls to be implemented and on personal protective equipment. It includes a special focus on building design and use of space.
This report describes a study that determined whether differences in national trends in tuberculosis (TB) incidence are attributable to the variable success of control programs or to biological, social, and economic factors. Trends in case notifications were used as a measure of trends in incidence in 135 countries from 1997-2006, and regression analysis was used to explore the associations between these trends and 32 measures covering aspects of development, the economy, the population, behavioral and biological risk factors, health services, and TB control.
This video illustrates the interactions between TB and HIV, including their impact on the immune system, TB testing, and TB treatment.
This video illustrates the interactions between TB and HIV, including their impact on the immune system, TB testing, and TB treatment.
This report was produced by a Federal TB task force that was reconvened by CDC in November 2006. The task force drafted an updated action plan to address the issue of multidrug-resistant TB (MDR TB) and extensively drug-resistant TB (XDR TB). Task force members were charged with articulating the most pressing problems, identifying barriers to improvement, and recommending specific action steps to improve prevention and control of XDR TB in their respective areas.
This report provides data on the mortality among patients with TB and associations with HIV infection. To investigate the impact of HIV on risk for death during TB treatment in the United States, data were analyzed for all culture-positive patients with TB from 1993 to 2008. The proportion that died was determined and stratified by HIV test result. Mortality data were restricted to patients reported before 2007.
This series of patient education fact sheets provides information on drugs used in the treatment of TB (e.g., Clofazimine, Ethambutol, Ethionamide, Isoniazid, Levofloxacin, Moxifloxacin, PASER [p-aminosalicylic acid granules], Pyrazinamide, Pyridoxine, Rifabutin, Rifampin, Streptomycin). The fact sheets include information on medication side effects, actions to take if side effects occur, and instructions in the event a dose of medication is missed.
Dr. Mark Gilbert of the BC Centre for Disease Control talks about tuberculosis in a minute-long video.
